SRC SIGNALING IN CANCER
Kitapta bölümler > Araştırma Kitabı · 2021
Yazarlar: Ayşe CANER, Elif Asik, Bulent Ozpolat
Tumor Microenvironmet-Siganling Pathways (B), Araştırma Kitabı, Springer, London/Berlin , A, Uluslararası, 2021, ss 23-33, İsviçre
Özet
<p><span lang="TR" style="font-size: 11pt; font-family: Arial, sans-serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Pioneering experiments performed by Harold Varmus and Mike Bishop in 1976, led to one of the most influential discoveries in cancer research and identified </span><span style="font-size: 11pt; font-family: Arial, sans-serif; letter-spacing: 0.15pt; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">the first cancer-causing oncogene</span><span lang="TR" style="font-size: 11pt; font-family: Arial, sans-serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"> called <em><span style="font-family:"Arial","sans-serif"">Src</span></em>. Later e</span><span lang="TR" style="font-size: 11pt; font-family: Arial, sans-serif; color: rgb(51, 51, 51); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">xperimental and clinical evidence suggested that Src kinase plays a significant role in promoting tumor growth and progression and its activity is assocated poor patient survival. Thus, several Src inhibitors were developed and approved by FDA for treatment of cancer patients. Tumor microenvironment (TME) is a highly complex </span><span lang="TR" style="font-size: 11pt; font-family: Arial, sans-serif; color: rgb(84, 84, 84); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"> and dynamic milieu where significant cross-talk occurs between cancer cells and TME-components, which consist </span><span lang="TR" style="font-size: 11pt; font-family: Arial, sans-serif; color: rgb(51, 51, 51); background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">of tumor-associated macrophages, fibroblasts, and other immune and vascular cells. Growth factors and chemokines activate multiple signaling cascades in TME and induce multiple kinases and pathways, including Src, leading to tumor growth, invasion/metastasis, angiogenesis, drug resistance and progression. Here, we will sytemically evaluate recent findings regarding regulation of Src and significance of targeting Src in cancer therapy</span><br></p>